Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urothelial Cancer 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Metastatic Urothelial Cancer 1Carcinoma, Transitional Cell 1

Interventions

Carboplatin 14pembrolizumab 12Gemcitabine 11Cisplatin 11Rituximab 8durvalumab 7Pemetrexed 6Nivolumab 6osimertinib 5atezolizumab 5Specimen Handling 5Paclitaxel 5Dexamethasone 5amivantamab 4Prednisone 4Ipilimumab 4Cyclophosphamide 4Bortezomib 4Bendamustine Hydrochloride 4tremelimumab 3trastuzumab deruxtecan 3olaparib 3niraparib 3lazertinib 3entrectinib 3enfortumab vedotin 3daratumumab 3belzutifan 3alectinib 3acalabrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × enfortumab vedotin × 90 days × Clear all
NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡